

# **Effects of cannabidiol on activated immune-inflammatory pathways in major depressive patients and healthy controls.**

(1) Muanpetch Rachayon<sup>1</sup>; (1) Ketsupar Jirakran; (2) Pimpayao Sodsai; (3) Siriwan Klinchanhom;  
(1) Atapol Sughondhabirrom; (4) Kitiporn Plaimas; (5) Apichat Suratanee; (1,6,7) Michael Maes

(1) Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand

(2) Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

(3) Division of Immunology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

(4) Advanced Virtual and Intelligent Computing (AVIC) Center, Department of Mathematics and Computer Science, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand

(5) Department of Mathematics, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok, Bangkok 10800, Thailand

(6) IMPACT Strategic Research Center, Barwon Health, Geelong, Australia; (7) Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

**Corresponding author:**

Prof. Dr Michael Maes, M.D., PhD.

Department of Psychiatry

Faculty of Medicine, Chulalongkorn University

Bangkok, 10330

Thailand

Email: [dr.michaelmaes@hotmail.com](mailto:dr.michaelmaes@hotmail.com)

[Michael Maes - Google Scholar](#)

e-mail addresses:

[muanpetch.mp@gmail.com](mailto:muanpetch.mp@gmail.com)

[kett.kett@hotmail.com](mailto:kett.kett@hotmail.com)

[yokpim@gmail.com](mailto:yokpim@gmail.com)

[siriwanklinchanhom@gmail.com](mailto:siriwanklinchanhom@gmail.com)

[atapol.s@gmail.com](mailto:atapol.s@gmail.com)

[kplaimas@gmail.com](mailto:kplaimas@gmail.com)

[apichat.s@sci.kmutnb.ac.th](mailto:apichat.s@sci.kmutnb.ac.th)

[dr.michaelmaes@hotmail.com](mailto:dr.michaelmaes@hotmail.com)

## Abstract

**Background** Major depressive disorder and a major depressive episode (MDD/MDE) are characterized by activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS). Cannabidiol (CBD) is a phytocannabinoid isolated from the cannabis plant which was reported to have antidepressant-like and anti-inflammatory effects. The aim of the present study is to examine the effects of CBD on IRS, CIRS, M1, T helper (Th)-1, Th-2, Th-17, T regulatory (Treg) profiles, and growth factors in depression and healthy controls.

**Methods** Culture supernatant of stimulated (5 µg/mL of PHA and 25 µg/mL of LPS) whole blood of 30 depressed patients and 20 controls was assayed for cytokines using the LUMINEX assay. The effects of three CBD concentrations (0.1 µg/mL, 1 µg/mL, and 10 µg/mL) were examined.

**Results** Depression was characterized by significantly increased Th-1, Th-2, Th-17, Treg, IRS, CIRS and neurotoxicity profiles. CBD 0.1 µg/mL did not have any immune effects. CBD 1.0 µg/mL decreased CIRS activities but increased growth factor production, while CBD 10.0 µg/mL suppressed Th-1, Th-17, IRS, CIRS, and a neurotoxicity profile and enhanced T cell growth and growth factor production. CBD 1.0 to 10.0 µg/mL dose-dependently decreased sIL-1RA, IL-8, IL-9, IL-10, IL-13, CCL11, G-CSF, IFN-γ, CCL2, CCL4, and CCL5, and increased IL-1β, IL-4, IL-15, IL-17, GM-CSF, TNF-α, FGF, and VEGF.

**Conclusion** CBD has very complex immunomodulatory effects which depend on the CBD dose. CBD does not normalize the activated immune profiles observed in depression while higher concentrations can worsen inflammatory processes.

**Key words:** depression, mood disorders, inflammation, neuroimmunomodulation, cytokines, biomarkers, psychiatry

## Introduction

Activated immune-inflammatory pathways are among the most important pathways involved in the pathophysiology of major depressive disorder (MDD) and a major depressive episode (MDE) in bipolar disorder [1-5]. Activation of the immune-inflammatory response system (IRS) in MDD/MDE is shown by a pro-inflammatory cytokine profile including activated M1 macrophage cells as indicated by elevated levels of interleukin (IL)-1 $\beta$ , IL-6, IL-8 (or CXCL-8), and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ); T helper-1 (Th-1) cells with increased interferon- $\gamma$  (IFN- $\gamma$ ), IL-2, and IL-12 levels; and activated Th-17 cells with increased IL-17 and IL-6 [1,2]. Depression (MDD/MDE) is not only accompanied by activation of the IRS but also by activation of the compensatory immune-regulatory system (CIRS), which tends to downregulate the primary immune response and hyperinflammation [1]. Activation of CIRS profiles in MDD/MDE is indicated by activated Th-2 cells with increased IL-4 and IL-5 levels, and activated T regulatory (Treg) cells, characterized by increased IL-10, a major negative immunoregulatory cytokine [1].

The imbalance between pro-inflammatory and anti-inflammatory cytokines plays an important role in the onset of depression [1]. Importantly, some cytokines or chemokines which are increased in MDD/MDE have neurotoxic effects including IRS cytokines (e.g., IL-1, IL-2, IL-6, IL-8, TNF- $\alpha$ , IFN- $\gamma$ ), some chemokines (e.g., CCL1, CCL2, CCL11, CCL5, CXCL8, CXCL10) and even CIRS cytokines (e.g., IL-4) [1,6]. Therefore, IRS and especially increased neurotoxic cytokines and chemokines are new drug targets in the treatment of MDD/MDE [7]. Antidepressants of different classes reduce the ex vivo stimulated production of M1 and Th1 cytokines and upregulate that of interleukin-10 [8, 9]. Maes et al. described that new more

adequate antidepressants should target the activated IRS and the associated oxidative and nitrosative stress and neurotrophic pathways [7].

There is emerging evidence that cannabidiol (CBD), a phytocannabinoid that is isolated from the cannabis plant, may have antidepressant activities as indicated in animal models of depression [10]. For example, in a rodent model of depression, CBD and imipramine have comparable antidepressant-like effects [11]. There is also evidence that CBD may reduce self-reported depression and anxiety in clinically depressive and anxiety patients [12]. The latter authors reviewed that CBD may improve neurotrophic pathways in the brain which are reduced in depressive-like behaviors and MDD/MDE, including hippocampal neurogenesis and synaptogenesis, and brain derived neurotrophic factor (BDNF) signaling in the prefrontal cortex and hippocampus [10]. In addition, CBD has also antioxidant effects [13-15].

CBD has a low affinity towards CB<sub>1</sub> and CB<sub>2</sub> receptors compared to other cannabinoids such as  $\Delta^9$ -tetrahydrocannabinol [16]. 2-arachidonoylglycerol (2AG) and anandamide (AEA) are endocannabinoids which can activate CB<sub>2</sub> receptors resulting in different effects on inflammatory processes [13]. For example, 2-AG may promote leukocyte adhesion and release chemokines that promote leukocyte recruitment [13, 17]. Endothelial cells cultured with 2-AG for one hour produce TNF- $\alpha$  during 24 hours [18]. On the other hand, AEA may decrease the production of cytokines such as IL-4, IL-6, CXCL-8, and IFN- $\gamma$  [19, 20] and may increase the anti-inflammatory cytokine IL-10 [21]. CB<sub>2</sub> knockout mice show an increased production of pro-inflammatory cytokines, increased leukocyte recruitment and increased tissue damage.[19, 22, 23], while CB<sub>2</sub> receptor agonists may promote anti-inflammatory effects.[15, 19, 24, 25] The CB<sub>1</sub> receptor also has immune modulatory effects whereby activation of CNS CB<sub>1</sub> receptors is accompanied by reduced production of reactive oxygen species (ROS) and decreased neuronal

tissue damage [15, 26]. On the other hand, activation of peripheral CB<sub>1</sub> receptors may aggravate inflammation via increasing ROS and activation of nuclear factor (NF)-κB [15]. As such, endocannabinoids have complex effects on immune system functions and may promote as well as inhibit inflammatory processes through the CB<sub>2</sub> receptors. In vivo treatment with a low dose of CBD may decrease TNF-α production in LPS-treated mice [27] and CBD at higher doses highly significantly attenuate the expression of pro-inflammatory cytokines by CD3<sup>+</sup> T cells including TNF-α, IL-2, IL-17, IFN-γ and GM-CSF (granulocyte colony stimulating factor) [28].

Thus, it is plausible that CBD may exert antidepressive effects by reducing M1, Th-1 or Th-17 pathways or increasing CIRS functions (e.g. IL-10 production) thereby reducing neuro-affective toxicity. Nevertheless, so far there is no evidence whether CBD may modulate the IRS and CIRS and M1, Th-1, Th-2 and Th-17 activities, and the production of chemokines and growth factors in patients with MDD/MDE.

Hence, the aim of the study is to examine the effects of CBD on M1, Th-1, Th-2, Th-17, Treg, IRS and CIRS profiles and cytokines, immune-related neurotoxicity, chemokines and growth factors. The specific hypotheses are a) CBD has anti-inflammatory effects by decreasing M1, Th-1, Th-17 and IRS profiles and enhancing Treg and CIRS functions; and b) CBD attenuates the increased M1, Th-1, Th-17 and IRS responses in depression.

## **Methods and Participants**

### **Participants**

We included 30 depressed outpatients recruited at the outpatient clinic of the Department of Psychiatry, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. We included participants of both sexes, aged 18 to 65 years old. They were diagnosed as suffering from MDD

or MDE according to DSM-5 criteria and showed moderate to severe depression as assessed with the Hamilton Depression Rating Scale (HAM-D). The healthy volunteers were both males and females in the same age range as the patients. They were recruited by word of mouth from the same catchment area as the patients, namely Bangkok, Thailand. Exclusion criteria for MDD/MDE patients were other DSM-5 axis 1 disorders including schizophrenia, schizoaffective disorders, obsessive compulsive disorder, post-traumatic stress disorder, psycho-organic disorders, and substance abuse disorders. Exclusion criteria for healthy volunteers were a diagnosis of any axis 1 DSM-5 disorder and a positive family history of MDD and bipolar disorder. Exclusion criteria for both patients and controls were a) allergic or inflammatory responses three months before the study; b) neuroinflammatory, neurodegenerative or neurological disorders including epilepsy, Alzheimer's disease, multiple sclerosis, and Parkinson's disease; c) (auto)immune or allergic diseases including chronic obstructive pulmonary disease, inflammatory bowel disease, psoriasis, diabetes type 1, asthma, cancer, inflammatory diseases, and rheumatoid arthritis, d) a lifetime history of immunomodulatory drugs treatments, e) recent treatments (3 months prior to the study) with therapeutic doses of antioxidant or omega-3 polyunsaturated fatty acid supplements, f) use of anti-inflammatory drugs (NSAID, steroids) one month prior to the study, and g) lactating or pregnant women. Part of the patients took psychotropic medication, namely sertraline (n=18), other antidepressants (n=8, including fluoxetine, venlafaxine, escitalopram, bupropion and mirtazapine), benzodiazepines n=22; atypical antipsychotics n=14, and mood stabilizers (n=4). Putative effects of these drug state variables were statistically controlled for.

All controls and patients provided written informed consent prior to participation in this study. The study was conducted according to International and Thai ethics and privacy laws.

Approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (#528/63), which is in compliance with the International Guidelines for Human Research protection as required by the Declaration of Helsinki, The Belmont Report, CIOMS Guideline and International Conference on Harmonization in Good Clinical Practice (ICH-GCP).

## **Clinical measurements**

Semi-structured interviews were conducted by a research assistant specialized in mood disorders. We used the HAM-D, 17 item version, administered by an experienced psychiatrist to measure the severity of depressive symptoms.[29]. The State-Trait Anxiety Inventory (STAI) Thai state version is a psychological inventory which is used to measure severity of state anxiety [30]. The Mini-International Neuropsychiatric Interview (M.I.N.I.) was used to assess psychiatric axis-1 diagnoses [31].

## **Assays**

After an overnight fast (at least 10 hours) 20 mL blood was sampled at 8.00 a.m. and collected in BD Vacutainer® EDTA (10 mL) and BD Vacutainer® SST™ (5 mL) tubes (BD Biosciences, Franklin Lakes, NJ, USA). The SST blood was kept at room temperature (30 min) to allow clotting and to collect serum. Both tubes were centrifuged at 1100 ×g (4°C, 10 min) and serum or plasma was aliquoted and kept at -80°C. The natural CBD (99.89% isolate) stock preparation was produced by Love Hemp Ltd, United Kingdom (batch 8406) and its quality was guaranteed by the Medical Cannabis Research Institute, College of Pharmacy, RSU, Bangkok, Thailand.

Whole blood cultures were used for the assay of IL-1 $\beta$ , sIL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, CCL10, FGF, GM-CSF, IFN- $\gamma$ , CXCL10, CCL2, CCL3, PDGF, CCL4, CCL5, TNF- $\alpha$ , VEGF, and G-CSF. **Electronic Supplementary File (ESF)** Table 1 shows a list with the names, abbreviations, and official gene symbols of all cytokines/chemokines/growth factors assayed in the present study. ESF, Table 2 shows a list of the different immune profiles examined in the current study.

The effects of CBD on these cytokines/growth factors were studied by stimulating whole blood with PHA and LPS and analyzing the levels of cytokine production in culture supernatant.[8, 9,32]. RPMI-1640 medium (Gibco Life Technologies, USA) with L-glutamine and phenol red and containing 1% of penicillin (Gibco Life Technologies, USA) were employed with (stimulated) or without (unstimulated) 5  $\mu$ g/mL PHA (Merck, Germany) + 25  $\mu$ g/mL lipopolysaccharide (LPS; Merck, Germany). 1.8 mL of either one of these two media was placed into 24-well sterile plates with 0.2 mL of whole blood, 1/10 diluted. Whole blood was seeded in the 24-well culture plates with CBD which dissolved with dimethyl sulfoxide (DMSO) to make 1 mg/ml of stock and kept at -80°C. For each subject, the specimens could be divided into 4 conditions, namely (1) stimulated with LPS+PHA and incubated 72 hours, and (2-4) stimulated with LPS+PHA and incubated 72 hours with three different concentration of CBD, namely CBD 0.1  $\mu$ g/mL, 1  $\mu$ g/mL and 10.0g/mL. Samples were incubated for 72 h in a humidified atmosphere at 37°C, 5% CO<sub>2</sub>. After incubation, the plates were centrifuged at 1500 rpm for 8 min. Supernatants were taken off carefully under sterile conditions, divided into Eppendorf tubes, and frozen immediately at -70°C until thawed for assay of the cytokines/growth factors in culture supernatant. These CBD concentrations were chosen based on prior research in humans showing therapeutic CBD serum/plasma levels in the 0.1-1.0  $\mu$ g/dL range and additionally a 10- fold

higher dose (10.0 µg/dL) which is obtained in the intestinal lymphatic system after more targeted treatment [28].

The cytokines were measured using a LUMINEX assay (BioRad, California, United States of America) which is bead-based multiplex method. In brief, supernatants were fourfold diluted with media and incubated with coupled magnetic beads for 30 min. Detection antibodies were then added followed by streptavidin-PE for 30 min and 10 min, respectively, before measuring the fluorescence intensities (FI) using the Luminex 200 machine. In the present study we used the (blank analyte subtracted) FI values in the statistical analysis because FI are generally a more appropriate choice than absolute concentration especially when multiple plates are used [33]. Table 1 shows the range of the FI values that fall within the concentration curve. All samples of all cytokines were well measurable, except IL-7, which showed too many values below the sensitivity of the assay and was, therefore, excluded. IL-13 showed the acceptable limit of 30% values lower than the sensitivity and could be included in the statistical analysis. The inter-assay CV values for all analyses are less than 11%.

## Statistical analysis

Chi-square tests were performed to determine relationships between categorical variables, while analysis of variance (ANOVA) was employed to compare scale variables across categories. We employed generalized estimating equations (GEE) analysis, repeated measures, to determine the impact of CBD treatment on the cytokine profiles and all cytokines/growth factors separately. The pre-specified GEE analyses, repeated measures (AR working correlation matrix, a linear scale response, and maximum likelihood estimate as scale parameter method), included fixed categorical effects of time (treatment with vehicle and 3 CBD concentrations), groups

(depression versus controls) and time-by-treatment interaction, sex, smoking, and continuous fixed covariates, namely age and BMI. Moreover, the unstimulated values of the respective immune profiles and separate cytokines/growth factors were used as additional covariates but this did not change the results (because there were no significant differences in the unstimulated values between time and groups; results not shown). The immune profiles were the primary outcome variables and if these yielded significant outcomes we also examined the separate cytokines/growth factors. The multiple effects of time or groups on the immune profiles were subjected to false discovery rate (FDR)  $p$  correction [34]. Moreover, we also entered the drug state, age, sex, BMI and smoking in the GEE analysis as additional predictors to rule out any effects of these possible confounders. The GEE technique enables us to account for important interactions and confounders when analyzing treatment effects at the subject level, while avoiding biased imputations caused by incomplete evaluations. Nevertheless, there were no missing values in any of the demographic, clinical or cytokines/growth factor data (except IL-7, which was deleted from the analyses) assessed in this study. We computed the estimated marginal mean values of the treatment and diagnostic groups and the treatment X group interactions and used (protected) pairwise contrasts (least significant difference at  $p=0.05$ ) to examine differences between the treatment conditions (CBD compared with vehicle) and the group x treatment interactions. The tests were two-tailed, and statistical significance was defined as  $p < 0.05$ . IBM SPSS windows version 28 was used to perform the statistical analyses. The statistical studies followed the International Conference on Harmonisation's E9 statistical guidelines (November 2005). Using a two-tailed test with a significance level of 0.05 and assuming a power of 0.80, an effect size of 0.2, two groups, 4 measurements with a

intercorrelations of around 0.4 showed that the estimated sample size for a repeated measurement design ANOVA would be around 44.

## Protein-protein (PPI) network and GO enrichment analysis

GO (biological processes, [geneontology.org](http://geneontology.org)) enrichment analyses were performed separately on the upregulated and downregulated differentially expressed proteins (DEPs) using the R package clusterProfiler [35] and GO.db [36]. The dotplots and the results of the enrichment analysis are always shown using FDR corrected p-values and q-values. The PPI was constructed based on our DEP list and the gene members of the obtained GO terms. All interactions among the DEPs were retrieved from STRING database version 11.5 [37] using a high confidence score > 0.900. In addition, we constructed an expanded PPI network around the upregulated DEPs using OmicsNet 2.0 ([OmicsNet](http://OmicsNet)) and the IntAct Molecular Interaction Database (<https://www.ebi.ac.uk/intact/> (accessed on 2-2-2022) and examined the PPI network for its enrichment terms using the REACTOME (European Bio-Informatics Institute Pathway Database) pathways (<https://reactome.org>, accessed on 19 September, 2021).

## Results

### *Demographic and clinical data*

**Table 1** shows the socio-demographic data and clinical data of the patients and controls in this study. There were no significant differences in sex distribution, education, and smoking between the study groups. Patients were somewhat younger and showed a higher BMI. Nevertheless, all those variables were controlled for by entering these data in the GEE analysis. The mean HAM-D and STAI scores were significantly higher in patients as compared with

controls, indicating that most patients suffered from medium to severe clinical depression and anxiety.

### *Effects of CBD*

**Table 2** shows the results of GEE analyses with the effects of treatment. CBD 0.1 µg/mL did not have significant effects on the immune profiles. CBD 1.0 µg/mL significantly increased the growth factor and reduced the CIRS profile. At 10.0 µg/mL, CBD significantly decreased Th-1, Th-17, CIRS and the neurotoxicity profiles but increased the growth factor and T cell growth profiles. The effects of time on these 7 immune profiles remained significant after FDR p correction (at the  $p=0.0012$  level).

There were no significant effects of any of drugs on any of the immune profiles (even without FDR p correction). For example, there were no significant effects of sertraline ( $p=0.528$ ), other antidepressants ( $0.982$ ), benzodiazepines ( $p=0.944$ ), and atypical antipsychotics ( $p=0.172$ ) on the Th-1 profile while the effects of treatment remained significant at  $p<0.001$ . In addition, we have also examined the interaction between the drug state and the 4 conditions (vehicle and 3 CBD concentrations) but none of these was significant. For example, when examining the Th-1 profile, there were no significant interactions between time x sertraline ( $p=0.955$ ), other antidepressants ( $p=0.905$ ), benzodiazepines ( $p=0.545$ ), and antipsychotics ( $p=0.608$ ). Moreover, gender, age, BMI, and smoking did not affect any of the immune profiles even without FDR p correction.

**Table 3** shows the impact of CBD on the different cytokines/growth factors. CBD 0.1 µg/mL had no significant effects on any of the cytokines/growth factors. CBD 1.0 µg/mL significantly decreased the production of sIL-1RA, CXCL8, IL-9, IL-10, IL-13, CCL11, IFN- $\gamma$ ,

CCL2, CCL4, and CCL5, and increased the production of IL-1 $\beta$ , IL-2, IL-4, IL-15, FGF, GM-CSF, CXCL10, TNF- $\alpha$ , and VEGF. CBD 10.0  $\mu$ g/mL had a major impact on most immune markers (except IL-2). CBD 10.0  $\mu$ g/mL dose-dependently (from CBD 1.0 to 10.0  $\mu$ g/mL) increased IL-1 $\beta$ , IL-4, IL-15, IL-17, GM-CSF, TNF- $\alpha$ , FGF, VEGF, and decreased sIL-1RA, IL-6, CXCL8, IL-9, IL-10, IL-13, CCL11, G-CSF, IFN- $\gamma$ , CCL2, CCL3, CCL4, and CCL5. Such a dose-response was not found in the case of IL-2, CXCL10, and PDGF.

### *Differences depression versus controls.*

**Table 4** shows the results of the same GEE analyses as described in table 2 but with the focus on the group differences and time X group interactions (the latter are shown only when they are significant). Table 4 shows that the Th-2, Th-17, Th-2, IRS, CIRS, Tcell activation, and neurotoxicity profiles were all higher in depression than in controls, while all interaction terms were non-significant. These intergroup differences remained significant after applying FDR p correction (at  $p=0.0484$ ). **Table 5** shows the differences in the separate cytokines/growth factors between both groups: sIL-1RA, IL-5, IL-9, IL-12, IL-15, IL-17, FGF, G-CSF, IFN- $\gamma$ , CXCL10, TNF- $\alpha$ , and VEGF were significantly higher in depression than in controls. CCL3 was significantly lower in depression than in controls. There were significant interaction patterns for CXCL8, IL-10, GM-CSF, and CCL5. ESF, Figure 1 shows that depression patients have at the 3 CBD conditions lower GM-CSF than controls, whereas in control conditions there are no differences. ESF, Figure 2 shows that CCL5 levels were higher in patients than in controls in all 4 conditions. ESF Figure 3 shows the interaction pattern for CXCL8 indicating that this chemokine was higher in depressed patients than in the control, CBD 0.1 and 1.0  $\mu$ g/mL conditions, whereas those intergroup differences almost disappeared in the CBD 10.0  $\mu$ g/mL

condition. This indicates that the latter concentration tends to normalize the increased CXCL8 values. IL-10 levels were not significantly different between both groups at any condition, but while there was a trend towards higher levels in the control, 0.1 and 1.0 µg/mL conditions, there was a trend towards lowered levels in the 10.0 µg/mL condition in depression as compared with controls.

### *Enrichment analysis in the effects of CBD on Cytokines*

In this analysis we entered the DEPs which were upregulated and downregulated by 1.0 µg/mL. When performing annotation and enrichment analyses, the same GO terms with large gene members were often found in both the upregulated and downregulated networks. To avoid GO terms with a large member of genes, only enriched GOs with a size of their gene members < 90 genes were of interest. After that, we filtered to select the enriched GOs which contain our genes > 7% with a gene ratio > 25%. **Table 6** and **Figures 1** and **2** show the results and the dotplots of the GO enrichment analyses performed on the upregulated and downregulated genes. To delineate the relationship between these two sets of DEPs, we examined the protein interactions. The gene members in the GO:0042531 and GO:0048245 terms were aggregated and included in the up and downregulated DEP sets. All interactions among these genes were retrieved using STRING database version 11.5 [37] with a high confidence score > 0.9. Some genes that had no interactions with this criterion were then discarded from the plot; except VEGFA and IL9 which are in our DEP list. **Figure 3** displays the plot of all protein-protein interactions among these genes. VEGFA and IL9 were not found to interact with the other DEPs. IL-4 and CCL5 were present in both GO terms. The results show that CBD increases the regulation of tyrosine phosphorylation of STAT protein while it decreases eosinophil

chemotaxis. **Table 7** shows the REACTOME pathways that are over-represented in the enlarged PPI networks of the upregulated and downregulated DEPs.

## Discussion

### *Effects of CBD on immune profiles and cytokines/growth factors*

The first major finding of this study is that CBD 0.1  $\mu\text{g/mL}$  has no significant effects on any of the immune profiles, CBD 1.0  $\mu\text{g/mL}$  decrease CIRS activity and increases growth factor production, and that CBD 10.0  $\mu\text{g/mL}$  significantly suppresses Th-1, Th-17, IRS, CIRS, and neurotoxicity profiles, while increasing the growth factor and T cell growth profiles. Millar et al. [38] in a systematic review showed that the administration of CBD (oral route) used in human studies ranged between  $<1$  to 50 mg/kg/day [38]. The same authors [39] also published another systematic review on the pharmacokinetics of CBD administration and found that administration of 800 mg CBD (oral route) results in plasma concentrations of 0.221  $\mu\text{g/mL}$  (at 3.0 h) and 0.157  $\mu\text{g/mL}$  (at 4.0 h) [39], although other studies yielded a broader concentration range. Moreover, 20 mg CBD intravenously resulted in 0.686  $\mu\text{g/mL}$  3 minutes post administration [39]. Based on those results we decided to employ 0.1 and 1.0  $\mu\text{g/mL}$  CBD in our ex vivo experiments. Nevertheless, in the rodent, the concentrations in mesenteric lymph nodes were more than 50-fold higher than in the spleen and 250-fold higher than in plasma [28]. The latter authors ascertain that oral CBD coupled with dietary lipids may considerably increase delivery of CBD to the plasma and mesenteric lymphatic system. As such, lymphatic PBMCs may be exposed to high CBD concentrations in the 5-20  $\mu\text{g/mL}$  range when using this targeted approach, which will eventually be applied in patients with inflammatory disorders [28]. Accordingly, in our study we employed not only the 0.1 and 1.0  $\mu\text{g/mL}$  concentrations but also the 10.0  $\mu\text{g/mL}$  concentration.

It is important to note that, in animal studies, there is a significant association between plasma and brain CBD concentrations whereby a higher intake results in higher plasma and brain concentrations [40]. Therefore, we may conclude that CBD treatments, which normally use the low oral dosages, will not result in any significant effects on M1, Th-1, Th-2, Th-17, IRS, CIRS or the neurotoxic profiles and on the cytokines/growth factors measured here. Nevertheless, when using the higher intravenous dosage, CIRS functions may be suppressed as indicated by a significant suppression of IL-10, IL-13 and sIL-1RA production, while the dose-response effects of CBD 1.0 to 10.0 µg/mL indicate a reduced production of all CIRS products, and an increased production of IRS products including IL-6, CXCL-8, IL-9, CCL11, G-CSF, IFN-γ, CCL2, CCL3, CCL4, and CCL5.

These findings extend those of previous papers showing that CBD has a dose-related effect on immune cells [41]. Different studies established that CBD 1.0 – 10.0 µg/ml may suppress IFN-γ production by PBMCs [42-44]. Kozela *et al.* [44] found that CBD 1µM had an dose-related inhibitory effect on IL-6 production and Anil *et al.* [45] reported that CBD 4 µg/ml can reduce CXCL8 levels more than dexamethasone in a model of lung epithelial cells, although treatment with CBD in macrophages may result in increased CXCL8 levels [45]. Zgair *et al.* [28] observed that the expression of IFN-γ and GM-CSF by CD3+ T cells of multiple sclerosis patients, but not normal controls, was dose-dependently reduced by CBD 2.5–20 µg/mL.

On the other hand, our study established that CBD 1.0 to 10.0 µg/mL dose-dependently increased the production of growth factors including FGF and VEGF, and IL-1β, IL-4, IL-15, IL-17, GM-CSF, and TNF-α. As such, the higher therapeutic dosages and the targeted treatment with lipid-associated CBD may induce pro-inflammatory effects which linked to the anti-CIRS effects may have clinical relevance.

Our results extend those of previous papers showing that CBD 1  $\mu$ M had no effect on TNF- $\alpha$  production while CBD 10  $\mu$ M induced its production. [46]. On the other hand, an animal model revealed that higher concentrations of CBD (50  $\mu$ g/mL, 100  $\mu$ g/mL) can inhibit TNF- $\alpha$  production from microglia cells [47]. CBD 1.0  $\mu$ g/mL and 10  $\mu$ g/mL may enhance plasma IL-4 levels, whereas rodent studies showed that CBD 20 mg/kg/day (IV) may reduce plasma IL-4 levels [48]. Other studies established that CBD 1  $\mu$ M, but not 0.5  $\mu$ M, can inhibit IL1- $\beta$  secretion from monocytes [46] and that the dose-response curve of CBD 2.5 –20  $\mu$ g/dL indicated suppressant effects on IL-17, GM-CSF and TNF- $\alpha$ . In our study, CBD 1.0  $\mu$ g/mL, but not 10.0  $\mu$ g/mL, significantly increased IL-2 production. In this respect, Chen *et al.* reported that CBD may enhance or suppress IL-2 depending on the stimulus condition and that in strongly stimulated cells, CBD may suppress IL-2, but following lower stimuli CBD may enhance cytokine production [49]. Kaplan *et al.* investigated the effects of CBD in stimulated splenocytes and splenic T cells and found that CBD 1–10  $\mu$ M dose-dependently suppresses IL-2 production [43].

The above differences between studies may be explained by the different stimuli and models used to assess the immune network. We used a combination of LPS + PHA to stimulate diluted whole blood and analyzed cytokine and growth factor production in culture supernatant [8,9,50,51]. This diluted whole blood method more adequately reflects the *in vivo* cytokine production than assays on isolated PBMCs [8,9,50,51]. The method used in the present study retains all natural cell-to-cell connections, whereas techniques that isolate PBMC subtypes change the lymphocyte/monocyte ratio thereby affecting cytokine production [8,9,50,51]. Moreover, because some cytokines (including the master immunoregulatory cytokine IL-10) are

produced by macrophages, Th-0, Th-1, Th-2, and Treg cells [52], it is critical to assess IL-10 in whole blood cultures with conserved cell-to-cell interactions.

### *Differences in immune profiles in depression versus controls.*

The second major finding of this study is that depression is accompanied by increased production of the Th-1, Th-2, Th-17, and Treg cytokines and a partial activation of the M1 phenotype (increased production of TNF- $\alpha$ , sIL-1RA, and CXCL8) as compared with healthy controls. These findings support the results of a recent review showing that depression is accompanied by increased activities of M1, Th-1, Th-2, Th-17 and Treg cytokines [1].

Regarding the M1 macrophage profile, increased TNF- $\alpha$ , sIL-1RA and CXCL8 levels were also established in recent meta-analyses [53,54]. However, in the current study, the stimulated production of IL-6 was not elevated in depression, whereas increased serum/plasma IL-6 was established in MDD/MDE in reviews and a meta-analysis [4,53] while an early study found increased IL-6 in culture supernatant of PBMCs [55]. The current study and a recent meta-analysis [53] did not detect any changes in the stimulated production or serum/plasma levels of IL-1 $\beta$ , whereas an early study reported a higher stimulated production of IL-1 $\beta$  in MDD with melancholic features as compared with controls [55]. Köhler *et al.* also examined CXCL8 but they could not find any changes in MDD [53]. While, in the current study, CCL3 was significantly lower in depression, Köhler *et al.* [53] did not detect any differences in this chemokine. Nevertheless, as explained above, differences among studies may be explained by differences in the media used, e.g., culture supernatant of diluted whole blood versus serum/plasma, and also by differences in depression phenotypes, e.g. melancholia versus simple major depression.

Regarding the Th-1 profile, we found highly significant elevations in culture supernatant IFN- $\gamma$  and IL-12, but not IL-2, production in MDD/MDE. Some previous studies also reported increased IFN- $\gamma$  levels in MDD patients [56,57]. Moreover, lowered tryptophan and increased levels of tryptophan catabolites in MDD indicate that indoleamine 2,3-dioxygenase 1 (IDO1) may be stimulated by increased levels of IFN- $\gamma$  [58]. Daria *et al.* [59] found that serum IFN- $\gamma$  levels were decreased in treatment naïve MDD patients as compared with healthy controls and the Kohler *et al.* meta-analysis established decreased IFN- $\gamma$  levels in MDD [53]. Nevertheless, since IFN- $\gamma$  is difficult to measure in normal serum/plasma, reporting lowered levels in MDD as compared with controls is not really adequate. Previous studies found indicants of increased IL-2 mechanisms in MDD, including a higher percentage of patients with measurable IL-2, and increased serum sIL-2R levels and CD25+ bearing T cells) [60], whereas the current study did not detect that IL-2 is increased in culture supernatant of depressed patients. Nevertheless, our assay of IL-2 in culture supernatant may be less than adequate without anti-Tac antibodies as we discussed before [61]. Our results that IL-12 production is increased in depression further supports the finding of the Kohler *et al.* meta-analysis. Overall, it appears that Th-1 activation is a hallmark of depression whereas M1 macrophages are partially activated. Such findings support the theory of Maes *et al.* [62,63] that activated cell-mediated immune pathways including Th-1 activation are the most important hallmarks of depression [63].

We found significant increases in Th-2 cytokine production with increased levels of IL-5 and IL-9 in MDD patients, whereas there were no differences in IL-4 and IL-13. A previous meta-analysis [53] found that serum/plasma IL-13 levels were significantly elevated in MDD but that IL-4 and IL-5 did not significantly differ between groups. Other authors found increased IL-5 levels in medication-free MDD patients and in MDD patients with or without obesity as a

comorbidity [64,65]. Becerril *et al.* [66] reported that MDD patients have a higher level of IL-9 comparing with healthy controls.

Here we report that activation of the Th-17 T cell line as indicated by increased supernatant IL-17 production. Both the review by Maes and Carvalho [1] and the meta-analysis by Kohler *et al.* [53] showed that IL-17 levels are increased in depression. In the present study we identified that the IRS as well as CIRS immune profiles were higher in depression than in controls, which supports the review of Maes and Carvalho [1]. However, it should be stressed that the master regulatory cytokine IL-10 was not significantly higher in depression versus controls indicating that those CIRS functions are insufficient to damp IRS activation.

Importantly, in the current study we found that the neurotoxicity profile was significantly higher in patients than controls which was attributable to increased CXCL8, IL-12, IL-15, IL-17, TNF- $\alpha$ , IFN- $\gamma$ , CXCL10, and CCL5 levels. Such findings further support the neurotoxicity theory of both MDD/MDE which conceptualizes that increased levels of neurotoxic cytokines/chemokines exert neuro-affective toxicity on brain functions leading to depression [1]. These effects are additionally aggravated by increased nitro-oxidative stress, hypernitrosylation, and bacterial load, and lowered levels of neuroprotective antioxidants [67,68].

Interestingly, depression was also accompanied by increased levels of growth factors, including FGF, PDGF and VEGF. Previously, Wu *et al.*, in a meta-analysis, found higher peripheral FGF in MDD as compared with healthy controls [69]. They hypothesized that increases in peripheral FGF2 may be a compensatory effect in order to counter the increased oxidative stress and dysfunctional blood-brain-barrier [69]. Moreover, MDD patients who received treatments had lower levels of peripheral FGF [70]. We also found elevations of in PDGF and VEGF levels in MDD/MDE patients which extends the results of previous studies

[71-73]. Increased PDGF may constitute a compensatory response since exposure to prolonged stress and higher levels of pro-inflammatory cytokines may damage the blood-brain-barrier resulting in increased PDGF production [74,75]. However, Raymond *et al.* found no differences or even lower VEGF levels in MDD patients as compared with healthy controls [71].

### *CBD does not normalize the immune activation in depression, on the contrary*

The third major finding of our study is that CBD did not normalize the aberrations in the immune system in patients with MDD/MDE. This contrasts our a priori hypothesis that CBD may have antidepressive effects through regulation of immune-inflammatory processes. Even worse, CBD 1.0-10.0 µg/ml significantly reduced CIRS activity including suppressant effects on IL-10, sIL-1RA and IL-13, and increased FGF and VEGF production. However, CBD 10 µg/ml shows suppressive effect on Th-1, Th-17, CIRS, and the neurotoxic profile implying that different CBD dosages and different routes of administration may have different immune modulatory effects.

Moreover, annotation and enrichment analysis showed that 1.0 µg/mL CBD activated tyrosine phosphorylation of STAT protein, which may induce transcription of genes involved in immune cell activation and division and inflammation [76], cytokine signaling, and Toll Like Receptor signaling, which all play a role in depression [77]. As such, higher CBD concentrations may aggravate the immune pathophysiology of depression (and other inflammatory disease). In addition, the 1.0 µg/mL concentration also decreases eosinophil chemotaxis as well as the phosphatidylinositol signaling system (converting extracellular to intracellular signals and mediating cell metabolism, survival and proliferation), the forkhead box (FoxO) signaling pathway (mediating cell-cycle control and oxidative stress) and the sphingolipid signaling

pathways (producing sphingolipids which are involved in signal transduction) (<https://reactome.org>). Moreover, since CBD significantly decreases IL-10 production, we may conclude that treatments with CBD concentrations ranging from 1.0-1.0 µg/mL should be avoided in depression and probably in most immune and autoimmune disorders.

Apart from immune-inflammatory effects, CBD may modulate other pathways associated with depression. Firstly, CBD may modulate 5-HT<sub>1A</sub> receptors causing an anxiolytic-like and anti-depressive effects in rats [78,79]. Second, CBD can inhibit the cortisol axis in a mice model in association with antidepressant-like effects [80]. Third, administration of CBD may elevate BDNF levels in the prefrontal cortex and hippocampus which may be accompanied by antidepressant effects [81].

## Conclusions

CBD has very complex immunomodulatory effects that are dosage dependent. However, CBD does not normalize the activated immunological profiles associated with depression and, in the higher concentration range, may even worsen inflammatory responses and impair CIRS functions.

## Author's contributions

All the contributing authors have participated in the manuscript. M.M. and M.R. designed the study and M.M., K.P. and A.S. performed the network, enrichment, and annotation analyses. M.R. and K.J. recruited patients and controls. Assays were performed by P.S. and S.K. A.S.

secured financial support. All authors contributed to interpretation of the data and writing of the manuscript and agreed to publish the final version of the manuscript

### **Funding Statement**

AMERI-ASIA MED CO, Ltd, supported this work

### **Institutional Review Board Statements**

The study was conducted according to International and Thai ethics and privacy laws. Approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (#528/63)

### **Informed Consent Statement**

All controls and patients provided written informed consent prior to participation in this study

### **Data Availability Statement**

The dataset generated during and/or analyzed during the current study will be available from the corresponding author (M.M.) upon reasonable request and once the dataset has been fully exploited by the authors

### **Conflict of interest**

The authors have no conflict of interest with any commercial or other association in connection with the submitted article

## References

1. Maes, M.; Carvalho, A F. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder. *Mol. Neurobiol.* **2018**, 55 (12), 8885-8903 doi: 10.1007/s12035-018-1016-x
2. Leonard, B.; Maes, M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci. Biobehav. Rev.* **2012**, 36(2), 764-85. doi: 10.1016/j.neubiorev.2011.12.005. Epub 2011 Dec 19. PMID: 22197082.
3. Brunoni, A.R.; Supasitthumrong, T.; Teixeira, A.L.; Vieira, E.L.M.; Gattaz, W.F.; Benseñor, I.M.; Lotufo, P.A.; Lafer, B.; Berk, M.; Carvalho, A.F.; Maes, M. Differences in the immune-inflammatory profiles of unipolar and bipolar depression. *J. Affect. Disord.* **2020**, 262, 8-15 doi: 10.1016/j.jad.2019.10.037
4. Ogłodek, E.A.; Szota, A.; Just, M.J.; Moś, D.; Araszkiewicz, A. Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. *Pharmacol. Rep.* **2014**, 66 (5), 920-6 doi: 10.1016/j.pharep.2014.06.001
5. Eyre, H.A.; Air, T.; Pradhan, A.; Johnston, J.; Lavretsky, H.; Stuart, M. J.; Baune, B. T., A meta-analysis of chemokines in major depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2016**, 68, 1-8 doi: 10.1016/j.pnpbp.2016.02.006

6. Roomruangwong, C.; Noto, C.; Kanchanatawan, B.; Anderson, G.; Kubera, M.; Carvalho, A.F.; Maes, M. The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. *Mol. Neurobiol.* **2020**, 57(2), 778-797. doi: 10.1007/s12035-019-01737-z. Epub 2019 Aug 31. PMID: 31473906.
  
7. Maes, M.; Fišar, Z.; Medina, M.; Scapagnini, G.; Nowak, G.; Berk, M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. *Inflammopharmacol.* **2012**, 20(3), 127-50. doi: 10.1007/s10787-011-0111-7. Epub 2012 Jan 24. PMID: 22271002.
  
8. Maes, M.; Song, C.; Lin, A.H.; Bonaccorso, S.; Kenis, G.; De Jongh, R.; Bosmans, E.; Scharpé, S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. *Neuropsychopharmacol.* **1999**, 20(4), 370-9. doi: 10.1016/S0893-133X(98)00088-8. PMID: 10088138.
  
9. Kubera, M.; Lin, A.H.; Kenis, G.; Bosmans, E.; van Bockstaele, D.; Maes, M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. *J. Clin. Psychopharmacol.* **2001**, 21(2), 199-206. doi: 10.1097/00004714-200104000-00012. PMID: 11270917.

10. Silote, G.P.; Sartim, A.; Sales, A.; Eskelund, A.; Guimarães, F.S.; Wegener, G.; Joca, S. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. *J. Chem. Neuroanat.* **2019**, *98*, 104-116 doi: 10.1016/j.jchemneu.2019.04.006
  
11. Réus, G.Z.; Stringari, R.B.; Ribeiro, K.F.; Luft, T.; Abelaira, H.M.; Fries, G.R.; Aguiar, B.W.; Kapczinski, F.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Quevedo, J. Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. *Acta Neuropsychiatr.* **2011**, *23* (5), 241-8 doi: 10.1111/j.1601-5215.2011.00579.x
  
12. Martin, E.L.; Strickland, J.C.; Schlienz, N.J.; Munson, J.; Jackson, H.; Bonn-Miller, M O.; andrey, R. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. *Front. Psychiatry* **2021**, *12*, 729800 doi: 10.3389/fpsyt.2021.729800
  
13. Atalay, S.; Jarocka-Karpowicz, I.; Skrzydlewska, E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants (Basel)* **2019**, *9* (1), doi: 10.3390/antiox9010021
  
14. Borges, R.S.; Batista, J., Jr.; Viana, R.B.; Baetas, A.C.; Orestes, E.; Andrade, M.A.; Honório, K.M.; da Silva, A.B.F. Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. *Molecules* **2013**, *18* (10), 12663-12674 doi: 10.3390/molecules181012663

15. Morris, G.; Walder, K.; Berk, M.; Carvalho, A. F.; Marx, W.; Bortolasci, C. C.; Yung, A. R.; Puri, B. K.; Maes, M. Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2022**, *114*, 110481 doi: 10.1016/j.pnpbp.2021.110481
  
16. Pertwee, R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br. J. Pharmacol.* **2008**, *153* (2), 199-215 doi: 10.1038/sj.bjp.0707442
  
17. Jehle, J., Eich, L., Danisch, M., Bagheri, S., Avraamidou, E., Pfeifer, P., Tiyerili, V., Bindila, L., Lutz, B., Nickenig, G. The endocannabinoid 2-arachidonoylglycerol inhibits endothelial function and repair. *Int. J. Cardiol.* **2021**, *323*, 243-250 doi: 10.1016/j.ijcard.2020.08.042
  
18. Gasperi, V.; Evangelista, D.; Chiurchiù, V.; Florenzano, F.; Savini, I.; Oddi, S.; Avigliano, L.; Catani, M. V.; Maccarrone, M. 2-Arachidonoylglycerol modulates human endothelial cell/leukocyte interactions by controlling selectin expression through CB1 and CB2 receptors. *Int. J. Biochem. Cell. Biol.* **2014**, *51*, 79-88 doi: 10.1016/j.biocel.2014.03.028
  
19. Turcotte, C.; Blanchet, M. R.; Laviolette, M.; Flamand, N. The CB(2) receptor and its role as a regulator of inflammation. *Cell. Mol. Life Sci.* **2016**, *73* (23), 4449-4470 doi: 10.1007/s00018-016-2300-4

20. Chiurchiù, V.; Cencioni, M. T.; Bisicchia, E.; De Bardi, M.; Gasperini, C.; Borsellino, G.; Centonze, D.; Battistini, L.; Maccarrone, M. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. *Ann. Neurol.* **2013**, *73* (5), 626-36 doi: 10.1002/ana.23875
  
21. Correa, F.; Hernangómez, M.; Mestre, L.; Loría, F.; Spagnolo, A.; Docagne, F.; Di Marzo, V.; Guaza, C. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. *Glia* **2010**, *58* (2), 135-47 doi: 10.1002/glia.20907
  
22. Karsak, M.; Gaffal, E.; Date, R.; Wang-Eckhardt, L.; Rehnelt, J.; Petrosino, S.; Starowicz, K.; Steuder, R.; Schlicker, E.; Cravatt, B.; Mechoulam, R.; Buettner, R.; Werner, S.; Di Marzo, V.; Tüting, T.; Zimmer, A., Attenuation of allergic contact dermatitis through the endocannabinoid system. *Science* **2007**, *316* (5830), 1494-7 doi: 10.1126/science.1142265
  
23. Hegde, V.L.; Hegde, S.; Cravatt, B.F.; Hofseth, L.J.; Nagarkatti, M.; Nagarkatti, P.S., Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. *Mol. Pharmacol.* **2008**, *74* (1), 20-33 doi: 10.1124/mol.108.047035
  
24. Sheng, W.S.; Hu, S.; Min, X.; Cabral, G.A.; Lokensgard, J.R.; Peterson, P.K., Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. *Glia* **2005**, *49* (2), 211-9 doi: 10.1002/glia.20108

25. Montecucco, F.; Di Marzo, V.; da Silva, R. F.; Vuilleumier, N.; Capettini, L.; Lenglet, S.; Pagano, S.; Piscitelli, F.; Quintao, S.; Bertolotto, M.; Pelli, G.; Galan, K.; Pilet, L.; Kuzmanovic, K.; Burger, F.; Pane, B.; Spinella, G.; Braunersreuther, V.; Gayet-Ageron, A.; Pende, A.; Viviani, G. L.; Palombo, D.; Dallegri, F.; Roux-Lombard, P.; Santos, R. A.; Stergiopulos, N.; Steffens, S.; Mach, F. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. *Eur. Heart J.* **2012**, 33 (7), 846-56 doi: 10.1093/eurheartj/ehr449
26. Zoppi, S.; Pérez Nieves, B.G.; Madrigal, J.L. M.; Manzanares, J.; Leza, J. C.; García-Bueno, B., Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. *Neuropsychopharmacol.* **2011**, 36 (4), 805-818 doi: 10.1038/npp.2010.214
27. Petrosino, S.; Verde, R.; Vaia, M.; Allarà, M.; Iuvone, T.; Di Marzo, V. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. *J. Pharmacol. Exp. Therap.* **2018**, 365 (3), 652-663 doi: 10.1124/jpet.117.244368
28. Zgair, A.; Lee, J.B.; Wong, J.C. M.; Taha, D.A.; Aram, J.; Di Virgilio, D.; McArthur, J. W.; Cheng, Y.-K.; Hennig, I.M.; Barrett, D.A.; Fischer, P.M. Constantinescu, C.S.; Gershkovich, P., Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. *Sci. Reports* **2017**, 7 (1), 14542 doi: 10.1038/s41598-017-15026-z

29. Hamilton, M. A rating scale for depression. *J. Neurol. Neurosurg. Psychiatry* **1960** 23(1), 56-62. doi: 10.1136/jnnp.23.1.56. PMID: 14399272; PMCID: PMC495331.
30. Spielberger, C.; Gorsuch, R.; Lushene, R.; Vagg, P. R.; Jacobs, G. *Manual for the State-Trait Anxiety Inventory (Form Y1 – Y2)*. 1983; Vol. IV, doi:
31. Pettersson, A.; Modin, S.; Wahlström, R.; Winklerfelt Hammarberg, S.; Krakau, I. The Mini-International Neuropsychiatric Interview is useful and well accepted as part of the clinical assessment for depression and anxiety in primary care: a mixed-methods study. *BMC Family Practice* **2018**, 19 (1), 19 doi: 10.1186/s12875-017-0674-5
32. Kubera, M.; Kenis, G.; Bosmans, E.; Kajta, M.; Basta-Kaim, A.; Scharpe, S. Budziszewska, B.; Maes, M., Stimulatory effect of antidepressants on the production of IL-6. *Int. Immunopharmacol.* **2004**, 4 (2), 185-92 doi: 10.1016/j.intimp.2003.11.006
33. Breen, E.J.; Polaskova, V.; Khan, A. Bead-based multiplex immuno-assays for cytokines, chemokines, growth factors and other analytes: Median fluorescence intensities versus their derived absolute concentration values for statistical analysis. *Cytokine* **2015**, 71 (2), 188-198 doi: 10.1016/j.cyto.2014.10.030

34. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. Royal Statist. Soc. Series B (Methodological)* **1995**, 57 (1), 289-300 doi:
35. Wu, T.; Hu, E.; Xu, S.; Chen, M.; Guo, P.; Dai, Z.; Feng, T.; Zhou, L.; Tang, W.; Zhan, L.; Fu, X.; Liu, S.; Bo, X.; Yu, G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (N Y)* **2021**, 2 (3), 100141 doi: 10.1016/j.xinn.2021.100141
36. Caslson, M. *GO.db: A set of annotation maps describing the entire Gene Ontology. R package version 3.8.2.*, version 3.8.2.; 2019.
37. Szklarczyk, D.; Gable, A.L.; Nastou, K.C.; Lyon, D.; Kirsch, R.; Pyysalo, S.; Doncheva, N.T.; Legeay, M.; Fang, T.; Bork, P.; Jensen, L.J.; von Mering, C. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.* **2021**, 49 (D1), D605-d612 doi: 10.1093/nar/gkaa1074
38. Millar, S.A.; Stone, N.L.; Bellman, Z.D.; Yates, A.S.; England, T.J.; O'Sullivan, S.E. A systematic review of cannabidiol dosing in clinical populations. *Br. J. Clin. Pharmacol.* **2019**, 85 (9), 1888-1900 doi: 10.1111/bcp.14038

39. Millar, S.A.; Stone, N.L.; Yates, A.S.; O'Sullivan, S.E. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. *Front. Pharmacol.* **2018**, *9*, 1365 doi: 10.3389/fphar.2018.01365
40. Garberg, H.; Solberg, R.; Barlinn, J.; Martínez-Orgado, J.; Løberg, E.-M.; Saugstad, O. High-Dose Cannabidiol-Induced Hypotension after Global Hypoxia-Ischemia in Piglets. *Neonatology* **2017**, *112*, 143-149 doi: 10.1159/000471786
41. Burstein, S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. *Bioorganic Med. Chem.* **2015**, *23* (7), 1377-1385 doi: 10.1016/j.bmc.2015.01.059
42. Jenny, M.; Santer, E.; Pirich, E.; Schennach, H.; Fuchs, D.  $\Delta^9$ -Tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. *J. Neuroimmunol.* **2009**, *207* (1), 75-82 doi: 10.1016/j.jneuroim.2008.12.004
43. Kaplan, B.L.F.; Springs, A.E.B.; Kaminski, N.E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). *Biochem. Pharmacol.* **2008**, *76* (6), 726-737 doi: 10.1016/j.bcp.2008.06.022
44. Kozela, E.; Pietr, M.; Juknat, A.; Rimmerman, N.; Levy, R.; Vogel, Z. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-

activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. *J. Biol. Chem.* **2010**, 285 (3), 1616-1626 doi: 10.1074/jbc.M109.069294

45. Anil, S.M.; Shalev, N.; Vinayaka, A.C.; Nadarajan, S.; Namdar, D.; Belausov, E.; Shoval, I.; Mani, K.A.; Mechrez, G.; Koltai, H. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. *Sci. Reports* **2021**, 11 (1), 1462 doi: 10.1038/s41598-021-81049-2

46. Sermet, S.; Li, J.; Bach, A.; Crawford, R.B.; Kaminski, N.E. Cannabidiol selectively modulates interleukin (IL)-1 $\beta$  and IL-6 production in toll-like receptor activated human peripheral blood monocytes. *Toxicol.* **2021**, 464, 153016 doi: 10.1016/j.tox.2021.153016

47. Gugliandolo, E.; Licata, P.; Peritore, A.F.; Siracusa, R.; D'Amico, R.; Cordaro, M.; Fusco, R.; Impellizzeri, D.; Di Paola, R.; Cuzzocrea, S.; Crupi, R.; Interlandi, C.D. Effect of Cannabidiol (CBD) on Canine Inflammatory Response: An Ex Vivo Study on LPS Stimulated Whole Blood. *Vet. Sci.* **2021**, 8 (9), 185 doi: 10.3390/vetsci8090185

48. Mesiakaris, K.; Atsopardi, K.; Margarity, M.; Poulas, K. Cannabidiol pretreatment attenuates locomotor alterations and cytokine production in an autoimmune hepatitis model. *bioRxiv.* **2021**, 2021.04.19.440455 doi: 10.1101/2021.04.19.440455

49. Chen, W.; Kaplan, B.L.F.; Pike, S.T.; Topper, L.A.; Lichorobiec, N.R.; Simmons, S. O.; Ramabhadran, R.; Kaminski, N.E. Magnitude of stimulation dictates the cannabinoid-mediated

differential T cell response to HIVgp120. *J. Leukoc. Biol.* **2012**, 92 (5), 1093-1102 doi: 10.1189/jlb.0212082

50. De Groote, D.; Zangerle, P.F.; Gevaert, Y.; Fassotte, M. F.; Beguin, Y.; Noizat-Pirenne, F.; Pirenne, J.; Gathy, R.; Lopez, M.; Dehart, I.; et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. *Cytokine* **1992**, 4 (3), 239-48 doi: 10.1016/1043-4666(92)90062-v

51. Maes, M.; Song, C.; Lin, A.H.; Pioli, R.; Kenis, G.; Kubera, M.; Bosmans, E. In vitro immunoregulatory effects of lithium in healthy volunteers. *Psychopharmacol. (Berl)* **1999**, 143(4), :401-7. doi: 10.1007/s002130050965. PMID: 10367558.

52. Katsikis, P.D.; Wunderlich, E.S.; Smith, C.A.; Herzenberg, L.A.; Herzenberg, L.A. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. *J. Exp. Med.* **1995**, 181 (6), 2029-36 doi: 10.1084/jem.181.6.2029

53. Köhler, C.A.; Freitas, T.H.; Maes, M.; de Andrade, N.Q.; Liu, C.S.; Fernandes, B.S.; Stubbs, B.; Solmi, M.; Veronese, N.; Herrmann, N.; Raison, C.L.; Miller, B.J.; Lanctôt, K. L.; Carvalho, A.F. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatr. Scand.* **2017**, 135 (5), 373-387 doi: 10.1111/acps.12698

54. Leighton, S.P.; Nerurkar, L.; Krishnadas, R.; Johnman, C.; Graham, G.J.; Cavanagh, J. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. *Mol. Psychiatry* **2018**, *23* (1), 48-58 doi: 10.1038/mp.2017.205
55. Maes, M.; Scharpé, S.; Meltzer, H.Y.; Bosmans, E.; Suy, E.; Calabrese, J.; Cosyns, P. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. *Psychiatry Res.* **1993**, *49* (1), 11-27 doi: 10.1016/0165-1781(93)90027-e
56. Maes, M.; Scharpé, S.; Meltzer, H.Y.; Okayli, G.; Bosmans, E.; D'Hondt, P.; Vanden Bossche, B. V.; Cosyns, P. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. *Psychiatry Res.* **1994**, *54* (2), 143-60 doi: 10.1016/0165-1781(94)90003-5
57. Kahl, K. G.; Kruse, N.; Faller, H.; Weiss, H.; Rieckmann, P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. *Psychoneuroendocrinol.* **2002**, *27* (6), 671-81 doi: 10.1016/s0306-4530(01)00068-3
58. Insera, A.; Mastronardi, C.A.; Rogers, G.; Licinio, J.; Wong, M.L. Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma. *Mol. Neurobiol.* **2019**, *56* (6), 4288-4305 doi: 10.1007/s12035-018-1359-3

59. Daria, S.; Proma, M.A.; Shahriar, M.; Islam, S.M.A.; Bhuiyan, M.A.; Islam, M.R. Serum interferon-gamma level is associated with drug-naïve major depressive disorder. *SAGE Open Med.* **2020**, *8*, 2050312120974169 doi: 10.1177/2050312120974169
60. Maes, M.; Bosmans, E.; Suy, E.; Vandervorst, C.; De Jonckheere, C.; Raus, J. Immune Disturbances during Major Depression: Upregulated Expression of Interleukin-2 Receptors. *Neuropsychobiol.* **1990**, *24* (3), 115-120 doi: 10.1159/000119472
61. Maes, M. Interleukin-2 and schizophrenia. *Psychiatry Res.* **1998**, *77*(1), 63-4; author reply 65-6. doi: 10.1016/s0165-1781(97)00131-5. PMID: 10710177
62. Maes, M. Evidence for an immune response in major depression: a review and hypothesis. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **1995**, *19* (1), 11-38 doi: 10.1016/0278-5846(94)00101-m
63. Maes, M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2011**, *35* (3), 664-75 doi: 10.1016/j.pnpbp.2010.06.014
64. Dahl, J.; Ormstad, H.; Aass, H.C.; Malt, U.F.; Bendz, L.T.; Sandvik, L.; Brundin, L.; Andreassen, O.A. The plasma levels of various cytokines are increased during ongoing

depression and are reduced to normal levels after recovery. *Psychoneuroendocrinol.* **2014**, 45, 77-86 doi: 10.1016/j.psyneuen.2014.03.019

65. Schmidt, F.M.; Lichtblau, N.; Minkwitz, J.; Chittka, T.; Thormann, J.; Kirkby, K.C.; Sander, C.; Mergl, R.; Faßhauer, M.; Stumvoll, M.; Holdt, L.M.; Teupser, D.; Hegerl, U.; Himmerich, H. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. *J. Psychiatr. Res.* **2014**, 55, 29-34 doi: 10.1016/j.jpsychires.2014.04.021

66. Becerril-Villanueva, E.; Pérez-Sánchez, G.; Alvarez-Herrera, S.; Girón-Pérez, M.I.; Arreola, R.; Cruz-Fuentes, C.; Palacios, L.; de la Peña, F. R.; Pavón, L. Alterations in the Levels of Growth Factors in Adolescents with Major Depressive Disorder: A Longitudinal Study during the Treatment with Fluoxetine. *Med. Inflamm.* **2019**, 2019, 9130868 doi: 10.1155/2019/9130868

67. Maes, M.; Moraes, J.B.; Bonifacio, K.L.; Barbosa, D.S.; Vargas, H.O.; Michelin, A.P.; Nunes, S.O.V. Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach. *Metab. Brain Dis.* **2021**, 36(3), 509-521. doi: 10.1007/s11011-020-00656-6. Epub 2021 Jan 7. PMID: 33411213.

68. Simeonova, D.; Stoyanov, D.; Leunis, J.-C.; Murdjeva, M.; Maes, M. Construction of a nitro-oxidative stress-driven, mechanistic model of mood disorders: A nomothetic network approach. *Nitric Oxide* **2020**, 10:S1089-8603(20)30199-3, doi: 10.1016/j.niox.2020.11.001

69. Wu, C. K.; Tseng, P. T.; Chen, Y. W.; Tu, K. Y.; Lin, P. Y. Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: A preliminary meta-analysis under MOOSE guidelines. *Medicine (Baltimore)* **2016**, 95 (33), e4563 doi: 10.1097/md.0000000000004563
70. He, S.; Zhang, T.; Hong, B.; Peng, D.; Su, H.; Lin, Z.; Fang, Y.; Jiang, K.; Liu, X.; Li, H. Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. *Neurosci. Lett.* **2014**, 579, 168-172 doi: 10.1016/j.neulet.2014.07.035
71. Clark-Raymond, A.; Halaris, A. VEGF and depression: A comprehensive assessment of clinical data. *J. Psychiatr. Res.* **2013**, 47 (8), 1080-1087 doi: 10.1016/j.jpsychires.2013.04.008
72. Kahl, K.G.; Bens, S.; Ziegler, K.; Rudolf, S.; Kordon, A.; Dibbelt, L.; Schweiger, U. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. *Psychoneuroendocrinol.* **2009**, 34 (3), 353-357 doi: 10.1016/j.psyneuen.2008.09.016
73. Iga, J.-I.; Ueno, S.-i.; Yamauchi, K.; Numata, S.; Tayoshi-Shibuya, S.; Kinouchi, S.; Nakataki, M.; Song, H.; Hokoishi, K.; Tanabe, H.; Sano, A.; Ohmori, T. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2007**, 31 (3), 658-663 doi: 10.1016/j.pnpbp.2006.12.011

74. Arimura, K.; Ago, T.; Kamouchi, M.; Nakamura, K.; Ishitsuka, K.; Kuroda, J.; Sugimori, H.; Ooboshi, H.; Sasaki, T.; Kitazono, T., PDGF receptor  $\beta$  signaling in pericytes following ischemic brain injury. *Curr. Neurovasc. Res.* **2012**, 9 (1), 1-9 doi: 10.2174/156720212799297100
75. Jha, M.K.; Minhajuddin, A.; Gadad, B.S.; Trivedi, M.H. Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. *Int. J. Neuropsychopharmacol.* **2017**, 20 (11), 919-927 doi: 10.1093/ijnp/pyx060
76. Aaronson, D.S.; Horvath, C.M. A road map for those who don't know JAK-STAT. *Science* **2002**, 296(5573), 1653-5. doi: 10.1126/science.1071545. PMID: 12040185.
77. Lucas, K.; Maes, M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. *Mol. Neurobiol.* **2013**, 48(1), 190-204. doi: 10.1007/s12035-013-8425-7. Epub 2013 Feb 26. PMID: 23436141; PMCID: PMC7091222.
78. Zanelati, T.V.; Biojone, C.; Moreira, F.A.; Guimarães, F.S.; Joca, S.R. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT<sub>1A</sub> receptors. *Br. J. Pharmacol.* **2010**, 159 (1), 122-8 doi: 10.1111/j.1476-5381.2009.00521.x

79. Gomes, F.V.; Resstel, L.B.M.; Guimarães, F.S. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT<sub>1A</sub> receptors.

*Psychopharmacol.* **2011**, *213* (2), 465-473 doi: 10.1007/s00213-010-2036-z

80. Viudez-Martínez, A.; García-Gutiérrez, M.S.; Manzanares, J. Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress. *J. Psychopharmacol.* **2018**, *32* (12), 1379-1384 doi: 10.1177/0269881118805495

81. Sales, A.J.; Fogaça, M.V.; Sartim, A.G.; Pereira, V.S.; Wegener, G.; Guimarães, F.S.; Joca, S.R.L. Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex. *Mol. Neurobiol.* **2019**, *56* (2), 1070-1081 doi: 10.1007/s12035-018-1143-4



**Table 1** Demographic and clinical data of the depressed patients and healthy controls (HC) included in the present study

| Variables                | HC (n=20)   | Depression (n=30) | F/X <sup>2</sup> | df   | p      |
|--------------------------|-------------|-------------------|------------------|------|--------|
| Sex (Male / Female)      | 6 / 14      | 11 / 19           | 0.24             | 1    | 0.626  |
| Age (years)              | 33.6 (8.0)  | 28.7 (8.6)        | 4.28             | 1/48 | 0.04   |
| Education (years)        | 16.1 (2.2)  | 15.6 (1.4)        | 0.84             | 1/48 | 0.363  |
| BMI (kg/m <sup>2</sup> ) | 21.3 (2.5)  | 25.5 (5.9)        | 8.82             | 1/48 | 0.005  |
| HAM-D                    | 0.95 (1.59) | 23.5 (5.8)        | 281.87           | 1/48 | <0.001 |
| STAI                     | 37.7 (10.6) | 56.8 (7.2)        | 57.15            | 1/48 | <0.001 |
| Smoking (N/Y)            | 18 / 2      | 23 / 7            | FEPT             | -    | 0.285  |

Results are shown as mean  $\pm$ SD. F: results of analysis of variance; X<sup>2</sup>: analysis of contingency tables, FEPT: Fisher's exact probability test

BMI: body mass index; HAM-D: Hamilton Depression Rating Scale score; STAI: Spielberger State and Train Anxiety, State version

Table 2. Effects of cannabidiol (CBD) on lipopolysaccharide + phytohaemagglutinin-induced changes in various immune profiles

| Variables<br>(z scores) | Control <sup>a</sup>          | CBD 0.1 µg/mL <sup>b</sup>    | CBD 1.0 µg/mL <sup>c</sup>      | CBD 10 µg/mL <sup>d</sup>       | Wald   | df | p      |
|-------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|--------|----|--------|
| M1                      | -0.094 (0.122)                | -0.079 (0.143)                | -0.029 (0.118)                  | 0.114 (0.118)                   | 5.02   | 3  | 0.171  |
| Th-1                    | 0.045 (0.115) <sup>d</sup>    | 0.013 (0.125) <sup>c d</sup>  | 0.091 (0.121) <sup>b d</sup>    | -0.374 (0.110) <sup>a b c</sup> | 53.45  | 3  | <0.001 |
| Th-17                   | 0.018 (0.121) <sup>d</sup>    | -0.013 (0.128) <sup>d</sup>   | 0.012 (0.121) <sup>d</sup>      | -0.216 (0.124) <sup>a b c</sup> | 17.66  | 3  | 0.001  |
| Th-2                    | -0.038 (0.126)                | -0.037 (0.123)                | -0.075 (0.125)                  | -0.099 (0.119)                  | 0.96   | 3  | 0.812  |
| IRS                     | -0.008 (0.113)                | -0.116 (0.117)                | 0.004 (0.110)                   | -0.228 (0.106)                  | 22.53  | 3  | <0.001 |
| CIRS                    | 0.084 (0.131) <sup>c d</sup>  | 0.074 (0.133) <sup>c d</sup>  | -0.001 (0.126) <sup>a b d</sup> | -0.356 (0.104) <sup>a b c</sup> | 37.23  | 3  | <0.001 |
| Tcell                   | -0.150 (0.113) <sup>d</sup>   | -0.165 (0.112) <sup>d</sup>   | -0.114 (0.099) <sup>d</sup>     | 0.226 (0.108) <sup>a b c</sup>  | 36.30  | 3  | <0.001 |
| GF                      | -0.139 (0.109) <sup>c,d</sup> | -0.135 (0.107) <sup>c,d</sup> | -0.107 (0.107) <sup>a,b,d</sup> | 0.094 (0.117) <sup>a,b,c</sup>  | 155.52 | 3  | <0.001 |
| NT                      | 0.052 (0.117) <sup>d</sup>    | 0.018 (0.129) <sup>d</sup>    | 0.043 (0.122) <sup>d</sup>      | -0.303 (0.116) <sup>a b c</sup> | 35.84  | 3  | <0.001 |

Results of GEE analyses with immune profiles as dependent variables and time, group (depression versus controls) and time by group interactions as explanatory variables, and age, sex, and body mass index as covariates. Shown are the time effects (Wald) with <sup>a,b,c,d</sup>, indicating pairwise comparisons among the treatment conditions.

All data are shown as estimated marginal means (mean ±SE).

See ESF Table 2 for explanation of the profiles and cytokines measured in this study. IRS: immune-inflammatory response system, CIRS: compensatory immunoregulatory response system, Tcell: T cell growth, GF: growth factors, NT: neurotoxicity

Table 3 Effects of cannabidiol (CBD) on lipopolysaccharide + phytohaemagglutinin-induced changes in various cytokines / chemokines

| Variables<br>z scores | Control <sup>a</sup>          | CBD 0.1 µg/mL <sup>b</sup>    | CBD 1 µg/mL <sup>c</sup>        | CBD 10 µg/mL <sup>d</sup>       | Wald x2<br>(df=3) | p Value |
|-----------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|-------------------|---------|
| IL-1 $\beta$          | -0.461(0.090) <sup>c d</sup>  | -0.429 (0.092) <sup>c d</sup> | -0.230 (0.096) <sup>a b d</sup> | 1.144 (0.123) <sup>a b c</sup>  | 425.40            | <0.001  |
| IL-1RA                | 0.018 (0.090) <sup>c d</sup>  | 0.005 (0.089) <sup>d</sup>    | -0.007 (0.090) <sup>a d</sup>   | -0.230 (0.092) <sup>a b c</sup> | 168.27            | <0.001  |
| IL-2                  | -0.109 (0.124) <sup>c</sup>   | -0.105 (0.136) <sup>c</sup>   | 0.103 (0.134) <sup>a b</sup>    | -0.018 (0.130)                  | 29.23             | <0.001  |
| IL-4                  | -0.272 (0.125) <sup>c d</sup> | -0.227 (0.142) <sup>c d</sup> | -0.096 (0.137) <sup>a b d</sup> | 0.551 (0.137) <sup>a b c</sup>  | 61.81             | <0.001  |
| IL-6                  | 0.167 (0.130) <sup>d</sup>    | 0.152 (0.140) <sup>d</sup>    | 0.124 (0.125) <sup>d</sup>      | -0.484 (0.118) <sup>a b c</sup> | 105.82            | <0.001  |
| CXCL8                 | 0.091 (0.127) <sup>c d</sup>  | 0.091 (0.142) <sup>d</sup>    | -0.007 (0.108) <sup>a d</sup>   | -0.383 (0.021) <sup>a b c</sup> | 21.10             | <0.001  |
| IL-9                  | -0.026 (0.116) <sup>c d</sup> | -0.038 (0.114) <sup>c d</sup> | -0.072 (0.109) <sup>a b d</sup> | -0.137 (0.107) <sup>a b c</sup> | 49.68             | <0.001  |
| IL-10                 | 0.433 (0.139) <sup>c d</sup>  | 0.384 (0.132) <sup>c d</sup>  | 0.119 (0.114) <sup>a b d</sup>  | -0.992 (0.022) <sup>a b c</sup> | 138.95            | <0.001  |
| IL-13                 | 0.266 (0.143) <sup>c d</sup>  | 0.246 (0.121) <sup>d</sup>    | 0.043 (0.133) <sup>a d</sup>    | -0.609 (0.079) <sup>a b c</sup> | 56.32             | <0.001  |
| IL-15                 | -0.133 (0.095) <sup>c d</sup> | -0.133 (0.099) <sup>c d</sup> | -0.093 (0.098) <sup>a b d</sup> | 0.056 (0.096) <sup>a b c</sup>  | 125.91            | <0.001  |
| IL-17                 | -0.140 (0.106) <sup>d</sup>   | -0.175 (0.108) <sup>c d</sup> | -0.107 (0.110) <sup>b d</sup>   | 0.146 (0.127) <sup>a b c</sup>  | 36.24             | <0.001  |
| CCL11                 | 0.127 (0.127) <sup>c d</sup>  | 0.079 (0.135) <sup>d</sup>    | 0.023 (0.135) <sup>a d</sup>    | -0.132 (0.110) <sup>a b c</sup> | 17.00             | <0.001  |
| FGF                   | -0.179 (0.107) <sup>c d</sup> | -0.177 (0.105) <sup>c d</sup> | -0.121 (0.106) <sup>a b d</sup> | 0.208 (0.101) <sup>a b c</sup>  | 143.85            | <0.001  |
| G-CSF                 | 0.046 (0.111) <sup>d</sup>    | 0.053 (0.114) <sup>d</sup>    | 0.034 (0.115) <sup>d</sup>      | -0.148 (0.100) <sup>a,b,c</sup> | 29.09             | <0.001  |
| GM-CSF                | -0.168 (0.137) <sup>c d</sup> | -0.133 (0.121) <sup>d</sup>   | -0.031 (0.122) <sup>a d</sup>   | 0.422 (0.132) <sup>a b c</sup>  | 31.88             | <0.001  |
| IFN- $\gamma$         | 0.277 (0.123) <sup>c d</sup>  | 0.251 (0.126) <sup>c d</sup>  | 0.196 (0.126) <sup>a b d</sup>  | -0.895 (0.071) <sup>a b c</sup> | 166.03            | <0.001  |
| CXCL10                | -0.030 (0.089) <sup>c d</sup> | -0.034 (0.090) <sup>c d</sup> | 0.009 (0.089) <sup>a b d</sup>  | -0.183 (0.117) <sup>a b c</sup> | 36.70             | <0.001  |

|               |                               |                               |                                 |                                 |        |        |
|---------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|--------|--------|
| CCL2          | 0.399 (0.147) <sup>c d</sup>  | 0.355 (0.143) <sup>c d</sup>  | 0.139 (0.140) <sup>a b d</sup>  | -0.819 (0.060) <sup>a b c</sup> | 159.52 | <0.001 |
| CCL3          | 0.079 (0.109) <sup>d</sup>    | 0.079 (0.109) <sup>d</sup>    | 0.077 (0.109) <sup>d</sup>      | 0.054 (0.112) <sup>a b c</sup>  | 35.39  | <0.001 |
| PDGF          | -0.034 (0.030) <sup>d</sup>   | -0.036 (0.026) <sup>d</sup>   | -0.037 (0.09) <sup>d</sup>      | 0.098 (0.043) <sup>a b c</sup>  | 14.77  | 0.002  |
| CCL4          | 0.168 (0.128) <sup>c d</sup>  | 0.147 (0.127) <sup>d</sup>    | 0.120 (0.123) <sup>a d</sup>    | -0.316 (0.117) <sup>a b c</sup> | 231.01 | <0.001 |
| CCL5          | 0.041 (0.094) <sup>c d</sup>  | 0.023 (0.096) <sup>c d</sup>  | -0.038 (0.096) <sup>a b d</sup> | -0.174 (0.083) <sup>a b c</sup> | 64.97  | <0.001 |
| TNF- $\alpha$ | -0.048 (0.091) <sup>c d</sup> | -0.041 (0.097) <sup>c d</sup> | -0.005 (0.099) <sup>a b d</sup> | 0.070 (0.091) <sup>a b c</sup>  | 13.30  | 0.004  |
| VEGF          | -0.124 (0.099) <sup>c d</sup> | -0.111 (0.101) <sup>c d</sup> | -0.084 (0.099) <sup>a b d</sup> | 0.042 (0.103) <sup>a b c</sup>  | 138.92 | <0.001 |

Results of GEE analyses with cytokines/chemokines as dependent variables and time, group (depression versus controls) and time by group interactions as explanatory variables. Shown are the time effects (Wald) with <sup>a,b,c,d</sup>, indicating pairwise comparisons among the treatment conditions

All data are shown as estimated marginal means (mean  $\pm$  SE)

See ESF Table 2 for explanation of the profiles and cytokines measured in this study

Table 4 Differences in lipopolysaccharide + phytohaemagglutinin-induced changes in various immune profiles between patients with clinical depression and healthy controls (HC)

| <b>Variables<br/>z values</b> | <b>HC</b>      | <b>Depression</b> | <b>Wald</b> | <b>df</b> | <b>p</b> |
|-------------------------------|----------------|-------------------|-------------|-----------|----------|
| M1                            | -0.131 (0.116) | 0.087 (0.205)     | 0.86        | 1         | 0.354    |
| Th-1                          | -0.337 (0.119) | 0.225 (0.198)     | 5.59        | 1         | 0.018    |
| Th-17                         | -0.299 (0.122) | 0.199 (0.204)     | 4.43        | 1         | 0.035    |
| Th-2                          | -0.374 (0.125) | 0.250 (0.196)     | 7.16        | 1         | 0.007    |
| IRS                           | -0.366 (0.114) | 0.244 (0.184)     | 7.91        | 1         | 0.005    |
| CIRS                          | -0.299 (0.169) | 0.199 (0.172)     | 4.18        | 1         | 0.041    |
| Tcell                         | -0.305 (0.110) | 0.203 (0.169)     | 6.64        | 1         | 0.011    |
| GF                            | -0.430 (0.029) | 0.287 (0.217)     | 10.71       | 1         | 0.001    |
| NT                            | -0.286 (0.125) | 0.190 (0.197)     | 4.09        | 1         | 0.043    |

Results of GEE analyses with immune profiles as dependent variables and time, group (depression versus controls) and time by group interactions as explanatory variables. Only the effects of groups are shown as the interactions between group and time were always non-significant (the time effects are shown in Table 2). All data are shown as estimated marginal means (mean  $\pm$  SE)

See ESF Table 2 for explanation of the profiles and cytokines measured in this study

Table 5 Differences in lipopolysaccharide + phytohaemagglutinin-induced changes in various cytokines/growth factors between patients with clinical depression and healthy controls (HC)

| Variables<br>z scores | HC             | Depression     | Effect | Wald  | df | p      |
|-----------------------|----------------|----------------|--------|-------|----|--------|
| IL-1RA                | -0.321 (0.106) | 0.214 (0.141)  | G      | 9.45  | 1  | 0.002  |
| IL-5                  | -0.442 (0.034) | 0.295 (0.217)  | G      | 11.02 | 1  | 0.001  |
| CXCL8                 | -0.312 (0.015) | 0.208 (0.192)  | G      | 7.30  | 1  | 0.007  |
|                       |                |                | G x T  | 8.85  | 3  | 0.031  |
| IL-9                  | -0.178 (0.064) | 0.118 (0.121)  | G      | 5.19  | 1  | 0.023  |
| IL-10                 | -0.083 (0.150) | 0.055 (0.134)  | G x T  | 13.34 | 3  | 0.004  |
| IL-12                 | -0.391 (0.067) | 0.261 (0.204)  | G      | 8.09  | 1  | 0.004  |
| IL-15                 | -0.455 (0.098) | 0.303 (0.178)  | G      | 12.81 | 1  | <0.001 |
| IL-17                 | -0.415 (0.073) | 0.277 (0.208)  | G      | 9.71  | 1  | 0.002  |
| FGF                   | -0.404 (0.093) | 0.269 (0.183)  | G      | 10.75 | 1  | 0.001  |
| G-CSF                 | -0.421 (0.013) | 0.281 (0.219)  | G      | 10.28 | 1  | 0.001  |
| GM-CSF                | 0.134 (0.166)  | -0.089 (0.181) | G x T  | 8.05  | 3  | 0.045  |
| IFN- $\gamma$         | -0.255 (0.145) | 0.170 (0.155)  | G      | 4.05  | 1  | 0.044  |
| CXCL10                | -0.357 (0.140) | 0.238 (0.129)  | G      | 9.48  | 1  | 0.002  |
| CCL3                  | 0.437 (0.009)  | -0.292 (0.220) | G      | 10.91 | 1  | 0.001  |
| CCL5                  | -0.223 (0.115) | 0.149 (0.140)  | G      | 4.21  | 1  | 0.040  |
|                       |                |                | G x T  | 8.11  | 3  | 0.044  |
| TNF- $\alpha$         | -0.246 (0.092) | 0.169 (0.148)  | G      | 6.19  | 1  | 0.013  |
| VEGF                  | -0.415 (0.112) | 0.277 (0.163)  | G      | 12.54 | 1  | <0.001 |


Results of GEE analyses with cytokines/growth factors as dependent variables and time, group (depression versus controls) and group by time interactions (G x T) as explanatory variables. The effects of groups and/or the interactions between group and time are shown when significant (the time effects are shown in Table 3). All data are shown as estimated marginal mean (mean  $\pm$ SE) values

Table 6 Results of GO enrichment analysis of biological processes performed on the upregulated and downregulated protein-protein interaction networks of the differently expressed proteins (DEPs) induced by cannabidiol (CBD, 1 µg/mL)


| ID         | Description (upregulated DEPs by CBD)                                             | Gene members | Gene ratio | p adjust | q value  |
|------------|-----------------------------------------------------------------------------------|--------------|------------|----------|----------|
| GO:0042531 | Positive regulation of tyrosine phosphorylation of STAT protein                   | 71           | 5/9        | 2.95E-08 | 6.33E-09 |
| GO:1901550 | Regulation of endothelial cell development                                        | 15           | 3/9        | 1.90E-06 | 4.08E-07 |
| GO:1903140 | Regulation of establishment of endothelial barrier                                | 15           | 3/9        | 1.90E-06 | 4.08E-07 |
| GO:0071677 | Positive regulation of mononuclear cell migration                                 | 25           | 3/9        | 6.56E-06 | 1.41E-06 |
| GO:1901099 | Negative regulation of signal transduction in absence of ligand                   | 36           | 3/9        | 1.37E-05 | 2.95E-06 |
| GO:2001240 | Negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 36           | 3/9        | 1.37E-05 | 2.95E-06 |
| GO:0030212 | Hyaluronan metabolic process                                                      | 37           | 3/9        | 1.45E-05 | 3.13E-06 |
| GO:0002714 | Positive regulation of B cell mediated immunity                                   | 40           | 3/9        | 1.62E-05 | 3.48E-06 |
| GO:0002891 | Positive regulation of immunoglobulin mediated immune response                    | 40           | 3/9        | 1.62E-05 | 3.48E-06 |
| GO:0050691 | Regulation of defense response to virus by host                                   | 40           | 3/9        | 1.62E-05 | 3.48E-06 |
| ID         | Description (downregulated DEPs by CBD)                                           | Gene members | Gene ratio | p adjust | q value  |
| GO:0048245 | Eosinophil chemotaxis                                                             | 19           | 4/10       | 4.82E-08 | 1.54E-08 |
| GO:0072677 | Eosinophil migration                                                              | 23           | 4/10       | 7.60E-08 | 2.42E-08 |
| GO:2000501 | Regulation of natural killer cell chemotaxis                                      | 9            | 3/10       | 6.95E-07 | 2.21E-07 |
| GO:0035747 | Natural killer cell chemotaxis                                                    | 11           | 3/10       | 1.15E-06 | 3.66E-07 |
| GO:0002544 | Chronic inflammatory response                                                     | 20           | 3/10       | 5.37E-06 | 1.71E-06 |
| GO:1901623 | Regulation of lymphocyte chemotaxis                                               | 27           | 3/10       | 1.09E-05 | 3.46E-06 |

Table 7. REACTOME pathway classifications of the differently expressed proteins (DEPs) in the enlarged protein-protein interaction networks of the upregulated and downregulated DEPs induced by cannabidiol (1.0 µg/mL)


| <b>Pathways in upregulated DEPs</b>   | <b>Total</b> | <b>Expected</b> | <b>Hits</b> | <b>p</b> | <b>FDR p</b> |
|---------------------------------------|--------------|-----------------|-------------|----------|--------------|
| Cytokine Signaling in Immune system   | 286          | 2.18            | 18          | 1.08E-12 | 1.51E-09     |
| TRIF-mediated TLR3/TLR4 signaling     | 87           | 0.665           | 10          | 6.88E-10 | 2.70E-07     |
| MyD88-independent cascade             | 88           | 0.672           | 10          | 7.71E-10 | 2.70E-07     |
| Toll Like Receptor 3 (TLR3) Cascade   | 88           | 0.672           | 10          | 7.71E-10 | 2.70E-07     |
| Activated TLR4 signalling             | 100          | 0.764           | 10          | 2.76E-09 | 7.75E-07     |
| <b>Pathways in downregulated DEPs</b> |              |                 |             |          |              |
| Phosphatidylinositol signaling system | 100          | 0.694           | 31          | 1.59E-46 | 5.33E-44     |
| FoxO signaling pathway                | 294          | 2.04            | 38          | 1.53E-42 | 2.57E-40     |
| Sphingolipid signaling pathway        | 189          | 1.31            | 29          | 2.06E-33 | 2.30E-31     |



**Figure 1.** Dotplots of enriched GO functions representing upregulated genes by cannabidiol (1.0 µg/mL).



**Figure 2.** Dotplots of enriched GO functions representing downregulated genes by cannabidiol (1.0 µg/mL).



**Figure 3** Protein-protein interaction network of high-confidence interactions of the upregulated and downregulated genes as well as gene members of GO:0042531 (positive regulation of phosphorylation of STAT protein) and GO:0048245 (eosinophil chemotaxis).

**Effects of cannabidiol on the activated immune-inflammatory pathways in major depressive patients and healthy controls.**

(1) Muanpetch Rachayon; (1) Ketsupar Jirakran; (2) Pimpayao Sodsa; (3) Siriwan Klinchanhom; (1) *Atapol Sughondhabirrom*; (4) Kitiporn Plaimas; (5) Apichat Suratane; (1,6,7) Michael Maes

(1) Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand

(2) Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

(3) Division of Immunology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

(4) Advanced Virtual and Intelligent Computing (AVIC) Center, Department of Mathematics and Computer Science, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand

(5) Department of Mathematics, Faculty of Applied Science, King Mongkut's University of Technology North Bangkok, Bangkok 10800, Thailand

(6) IMPACT Strategic Research Center, Barwon Health, Geelong, Australia; (7) Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

**ESF Table 1.** Cytokine, chemokines and growth factors examined in the current study

| <b>Protein abbreviations</b> | <b>Protein name</b>                                                              | <b>Gene Symbol</b> | <b>Number of samples that lower than sensitivity of the assay</b> |
|------------------------------|----------------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------|
| IL-1 $\beta$                 | Interleukin-1 $\beta$                                                            | IL1B               | 0                                                                 |
| IL-1RA                       | Interleukin-1 receptor antagonist                                                | IL1RN              | 0                                                                 |
| IL-2                         | Interleukin-2                                                                    | IL2                | 0                                                                 |
| IL-4                         | Interleukin-4                                                                    | IL4                | 0                                                                 |
| IL-5                         | Interleukin-5                                                                    | IL5                | 0                                                                 |
| IL-6                         | Interleukin-6                                                                    | IL6                | 0                                                                 |
| IL-7                         | Interleukin-7                                                                    | IL7                | 125 (out of 200)                                                  |
| CXCL8 / IL-8                 | C-X-C motif chemokine ligand 8                                                   | CXCL8              | 0                                                                 |
| IL-9                         | Interleukin-9                                                                    | IL9                | 0                                                                 |
| IL-10                        | Interleukin-10                                                                   | IL10               | 0                                                                 |
| IL-12                        | Interleukin-12                                                                   | IL12               | 1                                                                 |
| IL-13                        | Interleukin-13                                                                   | IL13               | 60 (out of 200)                                                   |
| IL-15                        | Interleukin-15                                                                   | IL15               | 0                                                                 |
| IL-17                        | Interleukin-17                                                                   | IL17               | 0                                                                 |
| CCL11                        | Eotaxin                                                                          | CCL11              | 0                                                                 |
| FGF2                         | Fibroblast growth factor 2, Basic fibroblast growth factor                       | FGF2               | 0                                                                 |
| G-CSF                        | Granulocyte Colony Stimulating Factor, Colony Stimulating Factor 3 (Granulocyte) | CSF3               | 0                                                                 |
| GM-CSF                       | Granulocyte-macrophage colony-stimulating factor, Colony-stimulating factor 2    | CSF2               | 0                                                                 |
| IFN- $\gamma$                | <i>Interferon-<math>\gamma</math></i>                                            | IFNG               | 0                                                                 |
| CXCL10 / IP-10               | C-X-C motif chemokine ligand 8, Interferon gamma-induced protein 10              | CXCL10             | 0                                                                 |
| CCL2 / MCP1                  | C-C Motif Chemokine Ligand 2                                                     | CCL2               | 0                                                                 |
| CCL3 / MIP-1 $\alpha$        | Macrophage inflammatory protein-1 alpha, C-C Motif Chemokine Ligand 3            | CCL3               | 0                                                                 |


|                      |                                                                                                            |       |   |
|----------------------|------------------------------------------------------------------------------------------------------------|-------|---|
| PDGF                 | Platelet Derived Growth Factor Subunit B                                                                   | PDGFB | 0 |
| CCL4 / MIP-1 $\beta$ | C-C Motif Chemokine Ligand 4, Macrophage Inflammatory Protein 1-Beta, Lymphocyte Activation Gene 1 Protein | CCL4  | 0 |
| CCL5 /RANTES         | C-C Motif Chemokine Ligand 5, Regulated Upon Activation, Normally T-Expressed, And Presumably Secreted     | CCL5  | 0 |
| TNF- $\alpha$        | Tumor Necrosis Factor-Alpha                                                                                | TNF   | 0 |
| VEGF                 | Vascular Endothelial Growth Factor                                                                         | VEGFA | 0 |

**ESF Table 2.** Description of the immune profiles used in this study

| <b>Immune Profile</b> | <b>Members</b>                                                                                                                 |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|
| <b>M1 macrophage</b>  | IL-1 $\beta$ , sIL-1RA, IL-6, TNF- $\alpha$ , CXCL8, CCL3                                                                      |
| <b>T helper-1</b>     | IL-2, IFN- $\gamma$ , IL-12                                                                                                    |
| <b>T helper-2</b>     | IL-4, IL-5, IL-9, IL-13                                                                                                        |
| <b>T helper-17</b>    | IL-6, IL-17                                                                                                                    |
| <b>IRS</b>            | IL-1 $\beta$ , IL-6, TNF- $\alpha$ , CXCL8, CCL3, IL-2, IFN- $\gamma$ , IL-12, IL-17, IL-15, G-CSF, GM-CSF, CXCL10, CCL5, CCL2 |
| <b>CIRS</b>           | IL-4, IL-10, sIL-1RA                                                                                                           |
| <b>Neurotoxicity</b>  | IL-1 $\beta$ , IL-6, TNF- $\alpha$ , CXCL8, CCL3, IL-2, IFN- $\gamma$ , IL-12, IL-17, CXCL10, CCL11, CCL5, CCL2                |
| <b>T cell growth</b>  | IL4, IL9, IL12, GM-CSF, IL-15                                                                                                  |
| <b>Growth factors</b> | FGF, PDGF, VEGF                                                                                                                |


IRS: immune-inflammatory response system; CIRS: compensatory immunoregulatory system

## GM-CSF




**ESF Figure 1.** Effects of the Interaction between diagnosis and cannabidiol (CBD) administration on the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) in culture supernatant

## CCL5-(RANTES)



**ESF Figure 2.** Effects of the Interaction between diagnosis and cannabidiol (CBD) administration on the production of CCL5 in culture supernatant

## CXCL8·(IL-8)¶



**ESF Figure 3.** Effects of the Interaction between diagnosis and cannabidiol (CBD) administration on CXCL8 production in culture supernatant